Saturday 17 October 2026
Export VECT’s income statement to Excel — free account
VectivBio Holding AG
VECT Healthcare Biotechnology
VectivBio Holding AG’s revenue for fiscal 2022 (year ended December 2022) was $27.3 million.
Follow VECT
| Older periods | Jun '21 | Dec '21 | Jun '22 | Dec '22 | |
|---|---|---|---|---|---|
P/E ratio |
+2 more quarters Free account |
— | — | 0.00 | 0.00 |
P/S ratio |
— | — | 0.00 | 0.00 | |
P/FCF ratio |
— | — | 0.00 | 0.00 | |
P/Operating CF |
— | — | (19.66) | (7.77) | |
P/B ratio |
— | — | 1.35 | 2.05 | |
Price to Tangible BV |
— | — | 1.65 | 2.34 | |
EV/Sales |
— | — | 0.00 | 0.00 | |
EV/EBITDA |
— | — | 0.00 | 0.00 | |
EV/Operating CF |
— | — | 0.00 | (1.28) | |
EV/FCF |
— | — | 0.00 | (1.28) | |
Quick Ratio |
4.56 | 6.02 | 4.41 | 9.01 | |
Current Ratio |
4.77 | 6.41 | 4.69 | 9.14 | |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 0.12% | 0.05% | 4.09% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.05 | |
Asset Turnover |
— | — | — | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
— | (0.19) | (0.14) | (0.31) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 144.67% | 2,491.38% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 74.05% | 0.00% | |
Intangible Assets out of Total Assets |
0.13 | 0.19 | 0.14 | 0.10 | |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | |
Graham Net Nets |
— | — | 0.61 | 0.43 | |
Graham Number |
— | — | 0.00 | 0.00 | |
Earnings Yield |
— | — | (85.00%) | (52.74%) | |
Free Cash Flow Yield |
— | — | 0.00% | (40.40%) | |
Revenue per Share |
0.00 | 0.00 | 0.73 | 0.03 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
— | (72.20) | (9.78) | (56.33) | |
Working Capital |
120.04 | 92.90 | 119.92 | 201.47 | |
Capital Expenditures |
— | (0.06) | (0.02) | (0.07) | |
Net Current Asset Value |
117.04 | 89.55 | 116.27 | 186.98 | |
EV/EBIT |
— | — | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
— | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | — | — | 1.20 | |
Average Assets |
— | — | — | 161.58 | |
Average Common Equity |
— | — | — | 122.80 |
Columns are period end dates